安利康药业已收到中国国家药品监督管理局对其依托考昔片的批准，该药物用于治疗骨关节炎和痛风等炎症性疾病。此批准标志着该公司在医药市场迈出了重要一步。该药物适用于急性与慢性炎症性疾病的症状缓解，以及急性痛风性关节炎和原发性痛经。 AI
排序理由 国家药品监管机构批准药品上市。[lever_c_demoted from significant: ic=1 ai=0.0]
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →
安利康药业在中国获批依托考昔片
本文如何被排名
- Signal score
- 0 / 100
- Composite score across the factors below. Higher = stronger signal that this story matters right now.
- Newsworthiness bucket
- Research
- 国家药品监管机构批准药品上市。[lever_c_demoted from significant: ic=1 ai=0.0]
- Source corroboration
- Single-source cluster
- Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
- Topics
- product, policy
- Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
- AI-industry relevance
- Low
- Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
- Story freshness
- 121 days old
- Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.
完整方法见我们的编辑标准。
报道来源 [1]
-
安利康：获得依托考昔片药品注册证
36氪获悉，昂利康公告，公司近日收到国家药监局签发的依托考昔片《药品注册证书》。依托考昔片适用于治疗骨关节炎急性期和慢性期的症状和体征、急性痛风性关节炎和原发性痛经。